https://multiplesclerosisresearchrepository.com/2025/08/29/rebuttal-letter-sent-to-drs-sabatino-jr-cree-and-hauser-at-ucsf/2025-08-29T23:39:16+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/08/16/effect-of-early-treatment-intensity-on-progression-independent-of-relapse-activity-and-disability-accumulation-in-multiple-sclerosis/2025-08-16T11:00:31+00:00monthlyhttps://multiplesclerosisresearchrepository.com/about/2025-08-03T14:17:15+00:00weekly0.6https://multiplesclerosisresearchrepository.com/2025/04/19/beware-headlines-like-this-these-two-drugs-may-be-the-best-to-treat-nerve-pain/2025-04-19T13:48:36+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/18/trigeminal-neuralgia-in-ms-pain-management-research/2025-04-18T18:37:06+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/18/placeo-outperformed-teriflunomide-in-some-significant-regards-per-fda-approval-data/2025-04-18T12:24:51+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/17/another-interesting-aspect-from-the-hercules-tolebrutinib-phase-3-clinical-trial-results-published-in-the-nejm/2025-04-17T10:40:18+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/10/email-sent-to-fda-office-of-scientific-investigations-office-of-compliance-cder-regarding-concern-about-the-assessment-and-reporting-of-the-adverse-event-of-increase-in-alt-in-the-tolebrutinib-for/2025-04-10T15:44:18+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/08/disability-patterns-in-multiple-sclerosis-a-meta-analysis-on-pira-and-raw-in-the-real-world-context-luca-prosperini-serena-ruggieri-shalom-haggiag-carla-tortorella-claudio-gasperini/2025-04-08T23:30:54+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/04/letter-to-american-academy-of-neurology-and-dr-alexander-rae-grant-re-practice-guideline-recommendations-summary-disease-modifying-therapies-for-adults-with-multiple-sclerosis-re-ocrelizumab-f/2025-04-04T11:17:17+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/02/letter-sent-to-dr-bruce-bebo-of-the-national-ms-society-about-his-comments-regarding-dr-amit-bar-ors-receipt-of-the-john-dystel-award/2025-04-02T11:00:19+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/02/follow-up-response-to-dr-david-hafler-regarding-his-nomination-of-dr-amit-bar-or-for-the-john-dystel-award/2025-04-02T10:58:55+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/04/02/letter-sent-to-dr-david-hafler-director-of-yale-ms-program-regarding-his-nomination-of-dr-amit-bar-or-for-the-john-dystel-award/2025-04-02T10:57:13+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/03/17/disturbing-and-concerning-information-from-a-nonclinical-animal-study-for-ocrevus-from-the-fda-approval-documentation-pharmacology-review/2025-03-17T23:17:34+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/03/17/concerning-and-disturbing-information-about-ocrevus-product-quality-from-the-fda-ocrevus-approval-documents/2025-03-17T23:15:47+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/03/05/please-comment-on-my-fda-citizen-petition-about-their-egregious-corrupt-and-non-evidence-based-approval-of-ocrevus-for-primary-progressive-multiple-sclerosis-ppms/2025-03-05T15:42:39+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/03/01/should-ocrelizumab-be-used-in-non-active-primary-progressive-multiple-sclerosis-time-for-a-re-assessment/2025-03-01T20:13:50+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/27/ocrevus-faers-fda-adverse-events-reporting-systemdata/2025-02-27T12:45:44+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/24/message-sent-to-fda-via-email-on-2-22-2025-inquiring-as-to-how-the-ocrevus-for-ppms-trial-wa25046-oratorio-was-simultaneously-both-an-adequate-and-well-controlled-trial-and-not-an-adequate-a/2025-02-24T12:26:22+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/24/message-sent-to-fda-this-morning-via-email-inquiring-why-the-fda-did-not-convene-an-advisory-committee-meeting-for-the-approval-of-ocrevus-for-ppms/2025-02-24T12:24:26+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/24/fda-bad-ad-complaint-submitted-today-about-ocrevus-for-ppms-submitted-to-fda-opdp/2025-02-24T12:16:30+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/23/message-sent-via-email-to-the-fda-today-inquiring-as-why-ocrevus-ocrelizumab-received-breakthrough-therapy-designation/2025-02-23T19:18:23+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/22/instances-where-this-document-says-the-ppms-trial-was-adequate-and-well-controlled-and-was-not-adequate-and-well-controlled-contradictory/2025-02-22T23:11:10+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/22/fda-ocrevus-approval-rrms-center-for-drug-evaluation-and-research-application-number-761053orig1s000-medical-reviews/2025-02-22T17:54:22+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/22/from-table-126-reviewer-table-proportion-of-patients-with-cdp12-or-cdpw12-by-subgroup-wa25046-ppms-trial-oratorio-itt-intention-to-treat-from-center-for-drug-evaluation/2025-02-22T17:17:50+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/21/the-prescription-drug-user-fee-act-much-more-than-user-fees/2025-02-21T13:25:05+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/13/information-from-reviewing-the-national-multiple-sclerosis-society-nmss-financial-statements-from-2015-2023/2025-02-13T17:32:06+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/12/eae-is-not-a-useful-model-for-demyelinating-disease-by-peter-o-behan-and-abhijit-chaudhuri-2014/2025-02-13T00:46:30+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/12/from-fda-cder-approval-package-for-rebif-interferon-beta-1a/2025-02-12T11:46:28+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/10/table-1-reviewer-table-fda-approved-treatments-for-relapsing-multiple-sclerosis-from-fda-cder-application-number-211855orig1s000-diroximel-fumarate-vumerity-clinical-reviewss/https://multiplesclerosisresearchrepository.com/wp-content/uploads/2025/02/20250210_074331.jpg20250210_074331https://multiplesclerosisresearchrepository.com/wp-content/uploads/2025/02/20250210_074323.jpg20250210_074323https://multiplesclerosisresearchrepository.com/wp-content/uploads/2025/02/20250210_074315.jpg20250210_0743152025-02-10T12:46:32+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/02/08/fda-approval-package-for-copaxone-nda-20-622-s-015-approval-date-7-2-2001/2025-02-08T21:05:02+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/31/correspondence-with-the-fda/2025-01-31T14:53:57+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/30/response-from-the-fda-regarding-my-request-for-further-information-about-the-copaxone-glatiramer-acetate-safety-communication-and-boxed-warning-that-they-put-on-1-22-25/2025-01-30T14:31:39+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/29/why-has-the-fda-indication-for-tysabri-natalizumab-been-changed-numerous-times/2025-01-29T20:26:02+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/neurodegeneration-in-ms-a-race-against-time-ectrims-22-january-2025/2025-01-23T14:20:57+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/links-to-posts-by-dr-gavin-giovannoni-about-pira-smouldering-ms/2025-01-23T14:16:09+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/progression-in-multiple-sclerosis-further-evidence-of-an-age-dependent-process-marcus-koch-et-al/2025-01-23T14:14:35+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/effect-of-immunomodulatory-medication-on-regional-gray-matter-loss-in-relapsing-remitting-multiple-sclerosis-a-longitudinal-mri-study-kerstin-bendfeldt-et-al/2025-01-23T14:13:54+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/multiple-sclerosis-enigmatic-factors-and-new-controversies-annabel-vila-et-al/2025-01-23T14:13:16+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/refuseniks-2-by-dr-gavin-giovannoni-3-4-2022/2025-01-23T14:12:33+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/320/2025-01-23T14:12:04+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/an-argument-for-broad-use-of-high-efficacy-treatments-in-early-multiple-sclerosis-james-m-stankiewicz-md/2025-01-23T14:11:27+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/23/advanced-central-nervous-system-imaging-biomarkers-in-radiologically-isolated-syndrome-a-mini-review-sara-collorone/2025-01-23T14:10:41+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/association-between-use-of-interferon-beta-and-progression-of-disability-in-patients-with-relapsing-remitting-multiple-sclerosis-by-afsaneh-shirani-md-et-al/2025-01-21T19:08:48+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/disability-as-an-outcome-in-ms-clinical-trials-by-gc-ebers-et-al/2025-01-21T19:08:03+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/mri-measures-and-their-relations-with-clinical-disability-in-relapsing-remitting-and-secondary-progressive-multiple-sclerosis-by-e-giugni-et-al/2025-01-21T19:07:24+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/relapse-associated-and-relapse-independent-contribution-to-overall-expanded-disability-status-scale-progression-in-multiple-sclerosis-patients-diagnosed-in-different-eras-by-noemi-mo/2025-01-21T19:06:50+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/real-world-evidence-of-ocrelizumab-treated-relapsing-multiple-sclerosis-cohort-shows-changes-in-progression-independent-of-relapse-activity-mirroring-phase-3-trials-by-j-ingwe/2025-01-21T19:06:20+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/contribution-of-relapse-associated-worsening-in-overall-disability-accrual-in-patients-with-relapsing-onset-multiple-sclerosis-a-mediation-analysis-by-bo-chen-et-al/2025-01-21T19:05:38+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/does-initial-high-efficacy-therapy-in-multiple-sclerosis-surpass-escalation-treatment-strategy-a-comparison-of-patients-with-relapsing-remitting-multiple-sclerosis-in-the-czech-and-swe/2025-01-21T19:04:58+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/harmonizing-definitions-for-progression-independent-of-relapse-activity-in-multiple-sclerosis-a-systematic-review-by-jannis-muller-md-et-al/2025-01-21T19:04:25+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/usual-suspect-lesions-appear-not-to-cause-most-severe-disability-in-ms-patients-by-buffalo-neuroimaging-analysis-center-friday-february-24th-2023/2025-01-21T19:03:51+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/the-relevance-of-neuroimaging-findings-to-physical-disability-in-multiple-sclerosis-rahsan-gocmen/2025-01-21T19:03:09+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/correlation-analysis-of-mri-lesion-load-and-clinical-measures-in-multiple-sclerosis-cohort-using-structured-clinical-documentation-support-toolkit-1880-afif-hentati-tiffani/2025-01-21T19:02:37+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/relapses-and-progression-of-disability-in-multiple-sclerosis/2025-01-21T19:00:24+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/multiple-sclerosis-is-primarily-a-neurodegenerative-disease-by-abhijit-chaudhuri/2025-01-21T18:59:13+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/from-chaudhuri-a-behan-po-multiple-sclerosis-looking-beyond-autoimmunity-j-r-soc-med-2005-jul987303-6-doi-10-1177-014107680509800703-pmid-15994589-pmcid-pmc1168912/2025-01-21T18:58:32+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/guideline-on-clinical-investigation-of-medicinal-products-for-the-treatment-of-multiple-sclerosis-draft-european-medicines-agency-20-september-2012-committee-for-medicinal-produ/2025-01-21T17:20:13+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/279/2025-01-21T17:19:26+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/impact-of-drug-diversity-on-treatment-effectiveness-in-relapsing-remitting-multiple-sclerosis-rrms-in-germany-between-2010-and-2018-real-world-data-from-the-german-neurotransdata-multiple/2025-01-21T17:18:37+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/patients-experiences-with-multiple-sclerosis-disease-modifying-therapies-in-daily-life-a-qualitative-interview-study-anna-sippel-et-al/2025-01-21T17:17:51+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/association-of-chronic-active-multiple-sclerosis-lesions-with-disability-in-vivo-martina-absinta-md-phd-et-al/2025-01-21T17:17:05+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/long-term-drug-treatment-in-multiple-sclerosis-safety-success-and-concerns-jakimovski-d-et-al/2025-01-21T17:16:16+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/blood-neurofilament-light-levels-segregates-treatment-effects-in-multiple-sclerosis-delcoigne-b-et-al/2025-01-21T17:15:42+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/microcystic-macular-oedema-thickness-of-the-inner-nuclear-layer-of-the-retina-and-disease-characteristics-in-multiple-sclerosis-a-retrospective-study-saidha-s-et-al/2025-01-21T17:14:56+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/visual-dysfunction-in-multiple-sclerosis-correlates-better-with-optical-coherence-tomography-derived-estimates-of-macular-ganglion-cell-layer-thickness-than-peripapillary-retinal-nerve/2025-01-21T17:14:16+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/effect-of-immunodulatory-medication-on-regional-gray-matter-loss-in-relapsing-remitting-multiple-sclerosis-a-longitudinal-mri-study-bendfeldt-k-et-al/2025-01-21T17:13:42+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/treatment-escalation-vs-immediate-initiation-of-highly-effective-treatment-for-patients-with-relapsing-remitting-multiple-sclerosis-data-from-2-different-national-strategies-spelma/2025-01-21T17:12:50+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/initial-high-efficacy-disease-modifying-therapy-in-multiple-sclerosis-a-nationwide-cohort-study/2025-01-21T17:12:11+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/association-of-initial-disease-modifying-therapy-with-later-conversion-to-secondary-progressive-multiple-sclerosis-brown-jwl/2025-01-21T17:11:34+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/clinical-outcomes-of-escalation-vs-early-intensive-disease-modifying-therapy-in-patients-with-multiple-sclerosis-harding-k/2025-01-21T17:10:56+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/efficacy-classification-of-modern-therapies-in-multiple-sclerosis-samjoo-ia/2025-01-21T16:56:51+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/disease-modifying-therapies-for-relapsing-remitting-multiple-sclerosis-a-network-meta-analysis-lucchetta-rc-et-al/2025-01-21T16:56:14+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/patient-preferences-for-attributes-of-multiple-sclerosis-disease-modifying-therapies-development-and-results-of-a-ratings-based-conjoint-analysis-wilson-ls-et-al/2025-01-21T16:55:42+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/retinal-imaging-with-optical-coherence-tomography-a-biomarker-in-multiple-sclerosis-fiona-costello/2025-01-21T16:55:04+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/timing-of-retinal-neuronal-and-axonal-loss-in-ms-a-longitudinal-oct-study-lj-balk-et-al/2025-01-21T16:54:36+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/disease-modifying-therapies-modulate-retinal-atrophy-in-multiple-sclerosis-a-retrospective-study-i-button-et-al/2025-01-21T16:54:04+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/intrathecal-lipid-specific-oligoclonal-igm-synthesis-associates-with-retinal-axonal-loss-in-multiple-sclerosis-alvarez-cermeno-jc-et-al/2025-01-21T16:53:33+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/relationships-between-retinal-axonal-and-neuronal-measures-and-global-central-nervous-system-pathology-in-multiple-sclerosis-saidha-s/2025-01-21T16:52:59+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/optical-coherence-tomography-reflects-brain-atrophy-in-multiple-sclerosis-a-four-year-study-saidha-s-et-al/2025-01-21T16:52:26+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/active-ms-is-associated-with-accelerated-retinal-ganglion-cell-inner-plexiform-layer-thinning-ratchford-jn-et-al-2/2025-01-21T16:51:51+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/in-vivo-evaluation-of-retinal-neurodegeneration-in-patients-with-multiple-sclerosis-tatrai-e/2025-01-21T16:51:16+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/progression-of-retinal-ganglion-cell-loss-in-multiple-sclerosis-is-associated-with-new-lesions-in-the-optic-radiations-klistorner-a-et-al/2025-01-21T16:50:40+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/association-of-retinal-and-macular-damage-with-brain-atrophy-in-multiple-sclerosis-dorr-j-et-al/2025-01-21T16:50:09+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/retinal-nerve-fiber-layer-is-associated-with-brain-atrophy-in-multiple-sclerosis-gordon-lipkin-e-et-al/2025-01-21T16:49:32+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/retinal-degeneration-in-primary-progressive-multiple-sclerosis-a-role-for-cortical-lesions-petracca-m-et-al/2025-01-21T16:46:25+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/the-association-between-retinal-nerve-fibre-layer-thickness-and-corpus-callosum-index-in-different-clinical-subtypes-of-multiple-sclerosis-vedat-cilingir-et-al/2025-01-21T16:45:37+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/retinal-layer-segmentation-in-patients-with-multiple-sclerosis-using-spectral-domain-optical-coherence-tomography-elena-garcia-martin-phd/2025-01-21T16:45:03+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/disease-course-heterogeneity-and-oct-in-multiple-sclerosis-lj-balk-p-tewarie/2025-01-21T16:44:29+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/degeneration-of-retinal-layers-in-multiple-sclerosis-subtypes-quantified-by-optical-coherence-tomography-albrecht-p-et-al/2025-01-21T16:43:47+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/benign-multiple-sclerosis-is-associated-with-reduced-thinning-of-the-retinal-nerve-fiber-and-ganglion-cell-layers-in-non-optic-neuritis-eyes-huang-link-ym-et-al/2025-01-21T16:43:16+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/retinal-ganglion-cell-analysis-in-multiple-sclerosis-and-optic-neuritis-a-systematic-review-and-meta-analysis-britze-j-et-al/2025-01-21T16:32:39+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/validation-of-inter-eye-difference-thresholds-in-optical-coherence-tomography-for-identification-of-optic-neuritis-in-multiple-sclerosis-bsteh-g-et-al/2025-01-21T16:31:18+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/optimal-intereye-difference-thresholds-by-optical-coherence-tomography-in-multiple-sclerosis-an-international-study-nolan-kenney-rc-et-al/2025-01-21T16:21:29+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/disability-progression-unrelated-to-relapses-in-relapsing-remitting-multiple-sclerosis-insights-from-the-swiss-multiple-sclerosis-cohort-study-lorscheider-j-et-al/2025-01-21T16:20:51+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/peripapillary-retinal-nerve-fiber-layer-as-measured-by-optical-coherence-tomography-is-a-prognostic-biomarker-not-only-for-physical-but-also-for-cognitive-disability-progression-in-multiple-s/2025-01-21T16:20:15+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/macular-ganglion-cell-inner-plexiform-layer-thinning-as-a-biomarker-of-disability-progression-in-relapsing-multiple-sclerosis-bsteh-g-et-al/2025-01-21T16:19:31+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/active-ms-is-associated-with-accelerated-retinal-ganglion-cell-inner-plexiform-layer-thinning-ratchford-jn-et-al/2025-01-21T16:19:01+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/retinal-layer-thinning-is-reflecting-disability-progression-independent-of-relapse-activity-in-multiple-sclerosis-gabriel-bsteh/2025-01-21T16:18:14+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/predicting-clinical-progression-in-multiple-sclerosis-after-6-and-12-years/2025-01-21T16:17:38+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/long-term-disability-trajectories-in-relapsing-multiple-sclerosis-patients-treated-with-early-intensive-or-escalation-treatment-strategies-pietro-iaffaldano/2025-01-21T16:16:58+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/clinical-effects-associated-with-five-year-retinal-nerve-fiber-layer-thinning-in-multiple-sclerosis-dejan-jakimovski/2025-01-21T16:16:24+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/influence-of-age-at-disease-onset-on-future-relapses-and-disability-progression-in-patients-with-multiple-sclerosis-on-immunomodulatory-treatment-v-von-wyl-et-al/2025-01-21T16:15:50+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/187/2025-01-21T16:15:24+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/multiple-sclerosis-current-and-emerging-disease-modifying-therapies-and-treatment-strategies-dean-m-wingerchuk-md-msc-frcpc-et-al/2025-01-21T16:14:43+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/evolution-of-disease-modifying-therapy-benefits-and-risks-an-argument-for-de-escalation-as-a-treatment-paradigm-for-patients-with-multiple-sclerosis-brandi-l-vollmer-et-al/2025-01-21T16:14:11+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/a-personalized-approach-in-progressive-multiple-sclerosis-the-current-status-of-disease-modifying-therapies-dmts-and-future-perspectivesby-emanuele-damico/2025-01-21T16:13:34+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/early-use-of-high-efficacy-disease%e2%80%91modifying-therapies-makes-the-difference-in-people-with-multiple-sclerosis-an-expert-opinion-massimo-filippi-et-al/2025-01-21T16:13:05+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/clinical-outcomes-of-escalation-vs-early-intensive-disease-modifying-therapy-in-patients-with-multiple-sclerosis-katharine-harding-et-al/2025-01-21T16:12:27+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/late-onset-ms-disease-course-and-safety-efficacy-of-dmts-maria-chaira-buscarinu-et-al/2025-01-21T16:11:57+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/early-predictors-of-conversion-to-secondary-progressive-multiple-sclerosis-mahdi-barzegar-et-al/2025-01-21T16:11:20+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/size-selective-neuronal-changes-in-the-anterior-optic-pathways-suggest-a-differential-susceptibility-to-injury-in-multiple-sclerosis-evangelou-n/2025-01-21T16:10:44+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/normal-appearing-white-matter-in-multiple-sclerosis-has-heterogeneous-diffusely-prolonged-t2-whittall-kp-et-al/2025-01-21T16:10:02+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/167/2025-01-21T16:05:33+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/predicting-cognitive-decline-in-multiple-sclerosis-a-5-year-follow-up-study-by-anand-j-c-eijlers-et-al/2025-01-21T16:04:48+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/accelerated-evolution-of-brain-atrophy-and-black-holes-in-ms-patients-with-apoe-epsilon-4-enzinger-c-et-al/2025-01-21T16:04:18+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/influence-of-apolipoprotein-e-epsilon4-genotype-on-brain-tissue-integrity-in-relapsing-remitting-multiple-sclerosis-de-stefano-n-et-al/2025-01-21T16:03:33+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/patients-lacking-the-major-cns-myelin-protein-proteolipid-protein-1-develop-length-dependent-axonal-degeneration-in-the-absence-of-demyelination-and-inflammation-garbern-jy-et-al/2025-01-21T16:02:55+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/changes-observed-in-multiple-sclerosis-using-magnetic-resonance-imaging-reflect-a-focal-pathology-distributed-along-axonal-pathways-arnold-dl/2025-01-21T16:02:21+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/correlates-of-ms-disability-assessed-in-vivo-using-aggregates-of-mr-quantities-mainero-c-et-al/2025-01-21T16:01:43+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/predicting-neuropsychological-abnormalities-in-multiple-sclerosis-benedict-rh-et-al/2025-01-21T16:01:06+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/cognitive-impairment-in-early-onset-multiple-sclerosis-pattern-predictors-and-impact-on-everyday-life-in-a-4-year-follow-up-amato-mp-et-al/2025-01-21T16:00:33+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/regional-brain-atrophy-is-associated-with-physical-disability-in-multiple-sclerosis-semi-quantitative-magnetic-resonance-imaging-and-relationship-to-clinical-findings-bakshi-r/2025-01-21T16:00:00+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/thalamic-neurodegeneration-in-multiple-sclerosis-cifelli-a-et-al/2025-01-21T15:56:30+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/localization-of-grey-matter-atrophy-in-early-rrms-a-longitudinal-study-audoin-b-et-al/2025-01-21T15:55:58+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/selective-caudate-atrophy-in-multiple-sclerosis-a-3d-mri-parcellation-study-bermel-ra-et-al/2025-01-21T15:55:24+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/141/2025-01-21T15:54:48+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/regional-brain-atrophy-evolves-differently-in-patients-with-multiple-sclerosis-according-to-clinical-phenotype-pagani-e-et-al/2025-01-21T15:54:04+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/regional-brain-atrophy-development-is-related-to-specific-aspects-of-clinical-dysfunction-in-multiple-sclerosis-jasperse-b-et-al/2025-01-21T15:53:33+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/focal-cortical-atrophy-in-multiple-sclerosis-relation-to-lesion-load-and-disability-charil-a-et-al/2025-01-21T15:53:00+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/grey-and-white-matter-volume-changes-in-early-rrms-a-2-year-longitudinal-study-by-tiberio-m-et-al/2025-01-21T15:52:28+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/early-development-of-multiple-sclerosis-is-associated-with-progressive-grey-matter-atrophy-in-patients-presenting-with-clinically-isolated-syndromes-dalton-cm-et-al/2025-01-21T15:51:55+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/transected-neurites-apoptotic-neurons-and-reduced-inflammation-in-cortical-multiple-sclerosis-lesions-peterson-jw/2025-01-21T15:31:52+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/neocortical-neuronal-synaptic-and-glial-loss-in-multiple-sclerosis-wegner-c-et-al/2025-01-21T15:31:20+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/inflammatory-demyelination-is-not-central-to-the-pathogenesis-of-multiple-sclerosis-bruck-w/2025-01-21T15:30:48+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/putting-magnetic-resonance-spectroscopy-studies-in-context-axonal-damage-and-disability-in-multiple-sclerosis-by-matthews-pm-et-al/2025-01-21T15:30:07+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/longitudinal-brain-volume-measurement-in-multiple-sclerosis-rate-of-brain-atrophy-is-independent-of-the-disease-subtype-kalkers-nf-et-al/2025-01-21T15:29:25+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/two-year-follow-up-study-of-primary-and-transitional-progressive-multiple-sclerosis-ingle-gt-et-al/2025-01-21T15:28:46+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/grey-matter-damage-predictors-the-evolution-of-primary-progressive-multiple-sclerosis-at-5-years-rovaris-m-et-al/2025-01-21T15:28:15+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/one-year-follow-up-study-of-primary-and-transitional-progressive-multiple-sclerosis-by-stevenson-vl-et-al/2025-01-21T15:27:44+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/focal-thinning-of-the-cerebral-cortex-in-multiple-sclerosis-sailer-m-et-al/2025-01-21T15:27:07+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/brain-atrophy-assessment-in-multiple-sclerosis-importance-and-limitations-antonio-giorgio-md-et-al/2025-01-21T15:26:24+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/the-association-of-apolipoprotein-e-apoe-genotype-and-cognitive-outcomes-in-multiple-sclerosis-a-systematic-review-and-meta-analysis-amirreza-naseri/2025-01-21T15:25:30+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/hla-genotype-as-a-marker-of-multiple-sclerosis-prognosis-a-pilot-study-andreas-p-lyasandropoulos/2025-01-21T15:24:34+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/hla-dr2-dose-effect-on-susceptibility-to-multiple-sclerosis-and-influence-on-disease-course-l-f-barcellos-et-al/2025-01-21T15:23:32+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/disease-modifying-therapies-for-relapsing-active-secondary-progressive-multiple-sclerosis-a-review-of-population-specific-evidence-from-randomized-clinical-trials-antonios-bayas-et/2025-01-21T15:23:00+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/the-faces-of-to-late-a-surprisingly-progressive-cohort-of-stable-relapsing-remitting-multiple-sclerosis-patients-alin-ciubotaru-et-al/2025-01-21T15:22:29+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/cadth-canadian-drug-expert-committee-recommendation-final-for-ocrelizumab-ocrevus/2025-01-21T15:21:45+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/interferons-in-relapsing-remitting-multiple-sclerosis-a-systematic-review-graziella-filippini-et-al/2025-01-21T15:20:57+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/randomized-controlled-trial-of-interferon-beta-1a-in-secondary-progressive-ms-clinical-results-secondary-progressive-efficacy-clinical-trial-of-recombinant-interferon-beta-a/2025-01-21T15:20:22+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/anti-inflammatory-disease-modifying-treatment-and-short-term-disability-progression-in-spms-lorscheider-j-et-al/2025-01-21T15:19:44+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/changes-in-disability-in-people-with-multiple-sclerosis-a-10-year-prospective-study-by-david-conradsson-et-al/2025-01-21T15:19:11+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/mri-as-an-outcome-of-in-multiple-sclerosis-clinical-trials-by-m-daumer-et-al/2025-01-21T15:18:41+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/clinical-trials-in-multiple-sclerosis-milestones-by-yinan-zhang-et-al/2025-01-21T15:18:05+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/identifying-multiple-sclerosis-subtypes-using-unsupervised-machine-learning-and-mri-data-by-arman-eshaghi-et-al/2025-01-21T15:17:26+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/toward-precision-phenotyping-of-multiple-sclerosis-by-david-pitt-md-et-al/2025-01-21T15:16:39+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/new-insights-into-multiple-sclerosis-clinical-course-from-the-topographical-model-and-functional-reserve-stephen-c-krieger-and-james-sumowski/2025-01-21T15:15:51+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/understanding-multiple-sclerosis-as-a-disease-spectrum-above-and-below-the-clinical-threshold-by-stephen-kireger-karin-cook-and-carrie-m-hersh/2025-01-21T15:15:03+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/anti-cd20-therapies-in-multiple-sclerosis-from-pathology-to-the-clinic-jerome-de-seze-et-al/2025-01-21T15:14:11+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/lessons-for-clinical-trials-from-natalizumab-in-multiple-sclerosis-by-abhiit-chaudhuri/2025-01-21T15:13:24+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/myelin-and-axon-pathology-in-multiple-sclerosis-assessed-by-myelin-water-and-multi-shell-diffusion-imaging-by-reza-rahmanzadeh-et-al/2025-01-21T15:12:39+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/disability-outcomes-in-patients-with-active-secondary-progressive-multiple-sclerosis-by-nathaniel-lizak-et-al/2025-01-21T15:11:30+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/anti-inflammatory-disease-modifying-treatment-and-short-term-disability-progression-in-spms-by-johannes-lorscheider-et-al/2025-01-21T15:09:58+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/defining-secondary-progressive-multiple-sclerosis-by-johannes-lorscheider-et-al/2025-01-21T15:09:24+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/association-of-intrathecal-immunoglobulin-g-synthesis-with-disability-worsening-in-multiple-sclerosis-by-christaine-gasperi-md-et-al/2025-01-21T15:08:47+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/toxicity-of-released-b-cell-products-in-multiple-sclerosis-effects-on-neurons-and-oligodendrocytes-by-leah-zuroff-amit-bar-or-et-al/2025-01-21T15:08:12+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/association-of-intrathecal-pleocytosis-and-igg-synthesis-with-axonal-damage-in-early-ms-by-sinah-engel-et-al/2025-01-21T15:07:30+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/patterns-and-predictors-of-multiple-sclerosis-phenotype-transition-by-luigi-pontieri-et-al/2025-01-21T15:06:55+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/association-of-higher-ocrelizumab-exposure-with-reduced-disability-progression-in-multiple-sclerosis-by-stephen-hauser-et-al/2025-01-21T15:05:16+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/association-between-conventional-mri-activity-and-disability-in-ms/2025-01-21T14:26:00+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/raw-vs-pira-in-ms-raw-is-not-significant/2025-01-21T14:25:00+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/raw-relapse-associated-worsening-vs-pira-progression-independent-of-relapse-activity-in-multiple-sclerosis/2025-01-21T14:23:50+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/conversion-from-cis-to-ms-research/2025-01-21T14:22:12+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/neurofilament-light-as-a-marker-predictor-of-severity-progression-conversion-to-spms-etc-in-ms/2025-01-21T14:20:47+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/hippocampus-in-ms-research/2025-01-21T14:08:33+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/subcortical-lesion-and-subpial-demyelination-damage-research/2025-01-21T14:07:42+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/brain-atrophy-in-ms-research/2025-01-21T14:06:21+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/gray-matter-atrophy-damage-and-disability-in-ms-research/2025-01-21T14:04:54+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/lack-of-efficacy-of-dmts-in-general-and-based-on-age-and-disease-stage-research/2025-01-21T14:01:34+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/fda-summary-review-avonex-interferon-beta-1a-pla-95-0979-ela-95-0975/2025-01-21T13:59:43+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/fda-summary-review-202992orig1s000-aubagio-teriflunomide/2025-01-21T13:58:55+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/kesimpta-fda-approval-package-application-number-125326orig1s070/2025-01-21T13:56:32+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/fda-summary-review-nda-204063-s-10-tecfidera-dimethyl-fumarate/2025-01-21T13:55:13+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/briumvi-fda-and-va-summary-reviews/2025-01-21T13:54:11+00:00monthlyhttps://multiplesclerosisresearchrepository.com/2025/01/21/from-fda-application-number-761053orig1s000-summary-review-ocrevus/2025-01-21T13:52:27+00:00monthlyhttps://multiplesclerosisresearchrepository.comdaily1.02025-08-29T23:39:16+00:00